Search results
Results from the WOW.Com Content Network
Mosunetuzumab, sold under the brand name Lunsumio, is a monoclonal antibody used for the treatment of follicular lymphoma. [ 2 ] [ 3 ] [ 5 ] It bispecifically binds CD20 and CD3 to engage T-cells. [ 2 ] [ 3 ] It was developed by Genentech .
Mosunetuzumab was approved for medical use in the European Union in June 2022. ... Epcoritamab was approved for medical use in the United States in May 2023, [22] [23
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...
This is the first class of non-opioid pain medication approved to treat moderate to severe acute pain approved by the FDA in more than 20 years. The U.S. Food and Drug Administration (FDA) on ...
WASHINGTON (Reuters) -President Donald Trump's foreign aid pause has forced a suspension of flights for more than 40,000 Afghans approved for special U.S. visas and at risk of Taliban retribution ...
Zoetis, the manufacturer behind the vaccine, announced the conditional approval Friday, saying in a news release its scientists had begun updating its existing avian flu vaccine in 2022.
Obinutuzumab has two black box warnings: hepatitis B reactivation and progressive multifocal leukoencephalopathy. [7] [5]In the clinical trial of obinutuzumab in combination with chlorambucil, participants experienced infusion reactions (69%; 21% grade 3/4), neutropenia (40%; 34% grade 3/4), thrombocytopenia (15%; 11% grade 3/4), anemia (12%), and pyrexia and cough (10% each).
Zenocutuzumab was approved for medical use in the United States in December 2024. [3] [4] [5] It is the first approval by the US Food and Drug Administration (FDA) of a systemic therapy for people with non-small cell lung cancer or pancreatic adenocarcinoma harboring an neuregulin 1 gene fusion. [3] The FDA considers it to be a first-in-class ...